Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...
Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...
Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million wit...
The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...
Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA&rdquo...
The Special Committee of the Board of Directors of 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME) today confirmed ...
LSPedia, a global leader in pharmaceutical traceability and supply chain SaaS solutions, has secured its second major U.S. government contract, the MMCAP I...
Biogen Inc. and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...
Alumis Inc. (Nasdaq: ALMS) and ACELYRIN, Inc. (Nasdaq: SLRN) today announced a definitive merger agreement, creating a powerhouse in immunology-focused b...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its board of directors has unanimously authoriz...
Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina ex...
© 2025 Biopharma Boardroom. All Rights Reserved.
